These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 25465125)

  • 1. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
    Harada H; Harada Y
    Cancer Sci; 2015 Apr; 106(4):329-36. PubMed ID: 25611784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic and molecular pathogenesis of myelodysplastic syndromes.
    Shallis RM; Ahmad R; Zeidan AM
    Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics factors associated with myelodysplastic syndromes.
    Macedo LC; Silvestre AP; Rodrigues C; de Alencar JB; Zacarias JM; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2015 Jun; 55(1):76-81. PubMed ID: 25976472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
    Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
    Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.
    Haider M; Duncavage EJ; Afaneh KF; Bejar R; List AF
    Am Soc Clin Oncol Educ Book; 2017; 37():480-494. PubMed ID: 28561687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
    Nazha A; Sekeres MA; Gore SD; Zeidan AM
    Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic basis of myelodysplastic syndromes.
    Ogawa S
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(3):107-121. PubMed ID: 32161209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
    Harada H
    Rinsho Ketsueki; 2017; 58(10):1941-1950. PubMed ID: 28978836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes.
    Cilloni D; Messa F; Carturan S; Arruga F; Defilippi I; Messa E; Gottardi E; Saglio G
    Ann N Y Acad Sci; 2004 Dec; 1028():400-8. PubMed ID: 15650265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
    Gill H; Leung AY; Kwong YL
    Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.